Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells
Ji-Youn Kim, Ho-Gyu Choi, Hae-Miru Lee, Geum-A Lee, Kyung-A Hwang, Kyung-Chul Choi
Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells
Bisphenol-A (BPA) has been considered as an endocrine disrupting chemical (EDC) because it can exert estrogenic properties. For bisphenol-S (BPS) and bisphenol-F (BPF) that are BPA analogs and substitutes, their risk to estrogen-dependent cancer has been reported rarely compared with the numerous cases of BPA. In this study, we examined whether BPA, BPS, and BPF can lead to the proliferation, migration, and epithelial mesenchymal transition (EMT) of MCF-7 clonal variant (MCF-7 CV) breast cancer cells expressing estrogen receptors (ERs). In a cell viability assay, BPA, BPS, and BPF significantly increased proliferation of MCF-7 CV cells compared to control (DMSO) as did 17β-estradiol (E2). In Western blotting assay, BPA, BPS, and BPF enhanced the protein expression of cell cycle progression genes such as cyclin D1 and E1. In addition, MCF-7 CV cells lost cell to cell contacts and acquired fibroblast-like morphology by the treatment of BPA, BPS, or BPF for 24 hours. In cell migration assay, BPA, BPS, and BPF accelerated the migration capability of MCF-7 CV cells as did E2. In relation with the EMT process, BPA, BPS, and BPF increased the protein expression ofN-cadherin, while they decreased the protein expression of E-cadherin. When BPA, BPS, and BPF were co-treated with ICI 182,780, an ER antagonist, proliferation effects were reversed, the expression of cyclin D1 and cyclin E1 was downregulated, and the altered cell migration and expression ofN-cadherin and E-cadherin by BPA, BPS, and BPF were restored to the control level. Thus, these results imply that BPS and BPF also have the risk of breast cancer progression as much as BPA in the induction of proliferation and migration of MCF-7 CV cells by regulating the protein expression of cell cycle-related genes and EMT markersvia the ER-dependent pathway.
human breast cancer cells / endocrine disrupting chemicals / bisphenol-A / bisphenol-S / bisphenol-F / epithelial-mesenchymal transition / migration
[1] |
Kim CW, Go RE, Choi KC . Treatment of BG-1 ovarian cancer cells expressing estrogen receptors with lambda-cyhalothrin and cypermethrin caused a partial estrogenicity via an estrogen receptor-dependent pathway[J]. Toxicol Res, 2015, 31(4): 331–337
Pubmed
|
[2] |
Diamanti-Kandarakis E , Palioura E , Kandarakis SA ,
Pubmed
|
[3] |
Choi KC, Jeung EB. The biomarker and endocrine disruptors in mammals[J]. J Reprod Dev, 2003, 49(5): 337–345
Pubmed
|
[4] |
Kopras E, Potluri V, Bermudez ML ,
Pubmed
|
[5] |
Jung EM, Choi KC, Yu FH ,
Pubmed
|
[6] |
Chen MY, Ike M, Fujita M . Acute toxicity, mutagenicity, and estrogenicity of bisphenol-A and other bisphenols[J]. Environ Toxicol, 2002, 17(1): 80–86
Pubmed
|
[7] |
Vandenberg LN, Chahoud I, Heindel JJ ,
Pubmed
|
[8] |
Staples CA, Dorn PB, Klecka GM ,
Pubmed
|
[9] |
Lee HR, Hwang KA, Park MA ,
Pubmed
|
[10] |
Lee HS, Park EJ, Oh JH ,
Pubmed
|
[11] |
Soto AM, Sonnenschein C. Environmental causes of cancer: endocrine disruptors as carcinogens[J]. Nat Rev Endocrinol, 2010, 6(7): 363–370
Pubmed
|
[12] |
Park MA, Choi KC. Effects of 4-nonylphenol and bisphenol A on stimulation of cell growth via disruption of the transforming growth factor-β signaling pathway in ovarian cancer models[J]. Chem Res Toxicol, 2014, 27(1): 119–128
Pubmed
|
[13] |
Russo J, Hasan Lareef M, Balogh G ,
Pubmed
|
[14] |
Murray TJ, Maffini MV, Ucci AA ,
Pubmed
|
[15] |
Ho SM, Tang WY, Belmonte de Frausto J,
Pubmed
|
[16] |
Rochester JR, Bolden AL. Bisphenol S and F: a systematic review and comparison of the hormonal activity of bisphenol a substitutes[J]. Environ Health Perspect, 2015, 123(7): 643–650
Pubmed
|
[17] |
Liao C, Liu F, Kannan K . Bisphenol s, a new bisphenol analogue, in paper products and currency bills and its association with bisphenol a residues[J]. Environ Sci Technol, 2012, 46(12): 6515–6522
Pubmed
|
[18] |
Liao C, Kannan K. A survey of alkylphenols, bisphenols, and triclosan in personal care products from China and the United States[J]. Arch Environ Contam Toxicol, 2014, 67(1): 50–59
Pubmed
|
[19] |
Hanahan D, Weinberg RA. The hallmarks of cancer[J]. Cell, 2000, 100(1): 57–70
Pubmed
|
[20] |
Champeris Tsaniras S , Kanellakis N , Symeonidou IE ,
|
[21] |
Son H, Moon A. Epithelial-mesenchymal transition and cell invasion[J]. Toxicol Res, 2010, 26(4): 245–252
Pubmed
|
[22] |
Gupta N, Duda DG. Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer[J]. J Biomed Res, 2016, 30(3): 181–185
Pubmed
|
[23] |
Thiery JP, Acloque H, Huang RY ,
Pubmed
|
[24] |
Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis[J]. Science, 2011, 331(6024): 1559–1564
Pubmed
|
[25] |
Oh K, Moon HG, Lee DS ,
Pubmed
|
[26] |
Chunhacha P, Sriuranpong V, Chanvorachote P . Epithelial-mesenchymal transition mediates anoikis resistance and enhances invasion in pleural effusion-derived human lung cancer cells[J]. Oncol Lett, 2013, 5(3): 1043–1047
Pubmed
|
[27] |
Li Y, Arao Y, Hall JM ,
|
[28] |
Sherr CJ. Cancer cell cycles[J]. Science, 1996, 274(5293): 1672–1677
Pubmed
|
[29] |
Santen RJ, Boyd NF, Chlebowski RT ,
Pubmed
|
[30] |
Giacalone PL, Daurés JP, Ouafik L ,
Pubmed
|
[31] |
Chung SH, Franceschi S, Lambert PF . Estrogen and ERalpha: culprits in cervical cancer[J]? Trends Endocrinol Metab, 2010, 21(8): 504–511
Pubmed
|
[32] |
Pelekanou V, Leclercq G. Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis[J]. Int J Dev Biol, 2011, 55(7-9): 869–878
Pubmed
|
[33] |
Conzen SD. Minireview: nuclear receptors and breast cancer[J]. Mol Endocrinol, 2008, 22(10): 2215–2228
Pubmed
|
[34] |
Derouiche S, Warnier M, Mariot P ,
Pubmed
|
[35] |
Folkerd EJ, Dowsett M. Influence of sex hormones on cancer progression[J]. J Clin Oncol, 2010, 28(26): 4038–4044
Pubmed
|
[36] |
Hsieh TH, Tsai CF, Hsu CY ,
Pubmed
|
[37] |
Saha Roy S, Vadlamudi RK. Role of estrogen receptor signaling in breast cancer metastasis[J]. Int J Breast Cancer, 2012, 2012: 654698.
|
[38] |
Yu L, Shi J, Cheng S ,
Pubmed
|
[39] |
Zheng S, Huang J, Zhou K ,
Pubmed
|
[40] |
Keri RA, Ho SM, Hunt PA ,
Pubmed
|
[41] |
Mlynarcikova A, Macho L, Fickova M . Bisphenol A alone or in combination with estradiol modulates cell cycle- and apoptosis-related proteins and genes in MCF7 cells[J]. Endocr Regul, 2013, 47(4): 189–199
Pubmed
|
[42] |
Bates S, Bonetta L, MacAllan D ,
Pubmed
|
[43] |
Meyerson M, Harlow E. Identification of G1 kinase activity for cdk6, a novel cyclin D partner[J]. Mol Cell Biol, 1994, 14(3): 2077–2086
Pubmed
|
[44] |
Barnes DM, Gillett CE. Cyclin D1 in breast cancer[J]. Breast Cancer Res Treat, 1998, 52(1–3): 1–15
Pubmed
|
[45] |
Keyomarsi K, O’Leary N, Molnar G ,
Pubmed
|
[46] |
Nielsen NH, Arnerlöv C, Emdin SO ,
Pubmed
|
[47] |
Xiao D, He J. Epithelial mesenchymal transition and lung cancer[J]. J Thorac Dis, 2010, 2(3): 154–159
Pubmed
|
[48] |
Graff JR, Herman JG, Lapidus RG ,
Pubmed
|
[49] |
Hazan RB, Phillips GR, Qiao RF ,
Pubmed
|
[50] |
Nakajima S, Doi R, Toyoda E ,
Pubmed
|
[51] |
Kim YS, Hwang KA, Hyun SH ,
Pubmed
|
/
〈 | 〉 |